TY - JOUR
T1 - Evaluating the administration costs of biologic drugs
T2 - development of a cost algorithm
AU - Tetteh, Ebenezer K.
AU - Morris, Stephen
N1 - Publisher Copyright:
© 2014, Tetteh and Morris; licensee Springer.
PY - 2014
Y1 - 2014
N2 - Biologic drugs, as with all other medical technologies, are subject to a number of regulatory, marketing, reimbursement (financing) and other demand-restricting hurdles applied by healthcare payers. One example is the routine use of cost-effectiveness analyses or health technology assessments to determine which medical technologies offer value-for-money. The manner in which these assessments are conducted suggests that, holding all else equal, the economic value of biologic drugs may be determined by how much is spent on administering these drugs or trade-offs between drug acquisition and administration costs. Yet, on the supply-side, it seems very little attention is given to how manufacturing and formulation choices affect healthcare delivery costs. This paper evaluates variations in the administration costs of biologic drugs, taking care to ensure consistent inclusion of all relevant cost resources. From this, it develops a regression-based algorithm with which manufacturers could possibly predict, during process development, how their manufacturing and formulation choices may impact on the healthcare delivery costs of their products.
AB - Biologic drugs, as with all other medical technologies, are subject to a number of regulatory, marketing, reimbursement (financing) and other demand-restricting hurdles applied by healthcare payers. One example is the routine use of cost-effectiveness analyses or health technology assessments to determine which medical technologies offer value-for-money. The manner in which these assessments are conducted suggests that, holding all else equal, the economic value of biologic drugs may be determined by how much is spent on administering these drugs or trade-offs between drug acquisition and administration costs. Yet, on the supply-side, it seems very little attention is given to how manufacturing and formulation choices affect healthcare delivery costs. This paper evaluates variations in the administration costs of biologic drugs, taking care to ensure consistent inclusion of all relevant cost resources. From this, it develops a regression-based algorithm with which manufacturers could possibly predict, during process development, how their manufacturing and formulation choices may impact on the healthcare delivery costs of their products.
KW - Administration costs
KW - Biologics
KW - Economic evaluation
KW - Formulation
KW - Manufacturing
UR - http://www.scopus.com/inward/record.url?scp=84908406345&partnerID=8YFLogxK
U2 - 10.1186/s13561-014-0026-2
DO - 10.1186/s13561-014-0026-2
M3 - Article
AN - SCOPUS:84908406345
SN - 1867-4828
VL - 4
JO - Journal of Internet Services and Applications
JF - Journal of Internet Services and Applications
IS - 1
ER -